Table 3. Univariate analysis of prognostic factors impacting OSPT and OS.

Variables	No.	Median-OSPT	P-value	Median-OS	P-value
Gender (n = 85)			0.438		0.374
Male	53	NA.		48
Female	32	57.2		NA.
Age (n = 85)			0.056		0.047
<40years	43	NA.		NA.
≥40years	42	27.6		32.9
WBC (n = 85)			0.774		0.691
<4*10E9/L	72	57.2		60.2
≥4*10E9/L	13	NA.		NA.
HB (n = 85)			0.545		0.566
<100 g/L	70	57.2		59.1
≥100 g/L	15	40.1		60.2
PLT (n = 85)			0.701		0.781
<50*10E9/L	54	NA.		NA.
≥50*10E9/L	31	57.2		60.2
BM blast (n = 85)			0.809		0.954
<5%	40	40.1		60.2
≥5%	45	57.2		NA.
WHO classification(n = 85)			0.554		0.582
RCUD/RCMD/MDS-U	38	40.1		60.2
RAEB-1	22	NA.		NA.
RAEB-2	25	57.2		59.1
IPSS (n = 84)			0.632		0.880
Low/Int-1	47	40.1		60.2
Int-2/High	37	NA.		59.1
Karyotype (n = 84)			0.918		0.965
Good	47	57.2		NA.
Int	28	40.1		48.0
Poor	9	NA.		NA.
Conditioning (n = 85)			0.056		0.043
MAC	78	NA.		NA.
RIC	7	8.17		11.2
Stem cell source (n = 85)			0.004		0.004
Marrow	17	22.9		23.2
PBSCs	43	NA.		NA.
Marrow + PBSCs	24	57.2		59.1
Cord	1	0.4		4.73
Therapies pre-HSCT(n = 85)			0.843		0.902
DAC ± chemotherapy	43	57.2		60.2
BSC	42	NA.		NA.
CR Pre-HSCT(n = 85)			0.249		0.290
Yes	13	NA.		NA.
No	72	40.1		60.2
Secondary MDS (n = 85)			0.525		0.563
Yes	12	16.1		33.4
No	73	57.2		60.2
ATG (n = 85)			0.025		0.016
Yes	39	NA.		NA.
No	46	22.9		27.2
Progressionpre-HSCT (n = 85)			0.506		0.520
Yes	16	19.0		22.7
No	69	57.2		60.2
Donor type (n = 85)			0.001		0.001
MSDs	38	22.9		27.2
MUDs	29	NA.		NA.
HIDs	18	NA.		NA.
Infection (n = 78)			0.053		0.094
Yes	52	27.6		33.5
No	26	57.2		NA.
aGVHD (n = 78)			0.795		0.877
Yes	43	57.2		59.1
No	35	NA.		NA.
aGVHD (n = 78)			0.524		0.631
No	35	NA.		NA.
I-II	25	NA.		NA.
III-IV	18	19.0		27.2
cGVHD (n = 67)			0.069		0.075
Yes	35	57.2		59.1
No	32	NA.		NA.
HC (n = 78)			0.922		0.720
Yes	20	NA.		48.0
No	58	57.2		59.1
EBV (n = 78)			0.013		0.013
Yes	16	NA.		NA.
No	62	27.6		33.4
CMV (n = 78)			0.232		0.212
Yes	28	NA.		NA.
No	50	31.1		48.0

OS: overall survival; OSPT: overall survival post transplant.